Peptide wave banner

News

November 18, 2010 — Lonza and California Peptide Research, Inc. (CPRI) have entered into a strategic collaboration to more effectively serve customers requesting peptide manufacturing and development services.

More »

April 15, 2010 — California Peptide Research, Inc. (CPRI) announced today it has been awarded a blanket purchase agreement (BPA) by the National Institutes of Health (NIH) for its peptide products and consulting services. The BPA is effective April 15, 2010 and has no purchase limit for the NIH research community.

More »

April 1, 2010 — California Peptide Research, Inc. (CPRI) announces the introduction of HFIP (hexafluoroisopropanol) treated beta amyloids to its existing catalog of neuropeptides. The new HFIP treated beta amyloids will be offered in the 1-40 and 1-42 variants in 1.0 mg and 0.5 mg quantities.

More »